2 terminated, 1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Malignant Ovarian Endometrioid Tumor: new trials by email Literature Review of Malignant Ovarian Endometrioid Tumor trials Research Report on Malignant Ovarian Endometrioid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
| Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Topotecan Hydrochloride, Acetylcysteine - Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 1 | 2015-10-02 | 2025-05-04 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (2) · Brenner Tumor (1)
Adnexal Diseases (3) · Fallopian Tube Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gonadal Disorders (2) · Ovarian Diseases (2)
130-nm albumin-bound paclitaxel (1) · Acetylcysteine (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Taxes (1) · Topotecan (1) · olaparib (1) · tremelimumab (1)
Gynecologic Oncology Group (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (4)
Katherine Bell-McGuinn (1) · Matthew S. Block, M.D., Ph.D. (1) · Russell Schilder, MD (1) · Sarah F Adams (1)
U10CA180868 (2), U10CA027469 (1)